Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin：a systematic review

方向; 胡世莲; 沈干; 吴蕾; 陈尹; 孙玉蓓; 徐婷娟; 徐维平

您当前的位置：

首页 >

文章列表页 >

Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin：a systematic review

更新时间：2026-01-09

- Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin：a systematic review
- Journal of Army Medical University Vol. 32, Issue 21, Pages: 2347-2351(2010)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R734.2;R969.4;R979.1
- Published：2010
- 稿件说明：
移动端阅览
方向,胡世莲,沈干,吴蕾,陈尹,孙玉蓓,徐婷娟,徐维平.吉西他滨联合顺铂方案与多西紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的系统评价[J].陆军军医大学学报(原第三军医大学学报),2010,32(21):2347-2351.

　Fang Xiang,Hu Shilian,Shen Gan,Wu Lei,Chen Yin,Sun Yubei,Xu Tingjuan,Xu Weiping.Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin：a systematic review[J].J Amry Med Univ (J Third Mil Med Univ),2010,32(21):2347-2351.
方向,胡世莲,沈干,吴蕾,陈尹,孙玉蓓,徐婷娟,徐维平.吉西他滨联合顺铂方案与多西紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的系统评价[J].陆军军医大学学报(原第三军医大学学报),2010,32(21):2347-2351. DOI：

　Fang Xiang,Hu Shilian,Shen Gan,Wu Lei,Chen Yin,Sun Yubei,Xu Tingjuan,Xu Weiping.Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin：a systematic review[J].J Amry Med Univ (J Third Mil Med Univ),2010,32(21):2347-2351. DOI：

摘要

目的比较吉西他滨联合顺铂方案(GP)与多西紫杉醇联合顺铂方案(DP)治疗晚期非小细胞肺癌的临床疗效和安全性。方法计算机检索Cochrane图书馆(2010年第1期)、Pubmed、CBM、CNKI、万方等数据库；纳入随机对照试验，采用Cochrane系统评价方法进行评价。结果共纳入16个研究1 670例晚期非小细胞肺癌患者，16个研究均未详细报道是否采用盲法。DP方案显示出与GP方案相当的中位生存期、中位疾病进展时间、有效率[RR=1.02，95%CI(0.89，1.15)]和生存率[1年RR=1.07，95%CI( 0.93，1.24)；2年RR=1.02，95%CI(0.66，1.58)]。15个研究的3~4级毒副作用合并结果显示，GP方案血小板减少、贫血、恶心呕吐发生率高于DP方案[RR=5.22，95%CI(2.97，9.18)；RR=1.76，95%CI(1.30，2.38)；RR=1.29，95%CI(1.04，1.60)]；GP方案白细胞减少及腹泻发生率低于DP方案[RR=0.71，95%CI(0.56，0.89)；RR=0.30，95%CI(0.15，0.60)]；两方案中性粒细胞减少、虚弱乏力的差异无统计学意义(P0.05)。结论在两方案疗效相近的情况下，选择GP方案或DP方案将取决于药物的毒性及患者的耐受性。

Abstract

Objective To compare the effect and safety of gemcitabine (GP) or docetaxel (DP) in combination with cisplatin for advanced non-small cell lung cancer (NSCLC). Methods Randomized controlled trials were searched from the Cochrane Library (first issue in 2010)

PubMed

CBM

CNKI

and Wanfang databases and evaluated using the Cochrane Collaboration’s software RevMan 5.0. Results Sixteen studies involving 1670 patients with NSCLC were included in this study. The blinding method was not reported in these studies. The median survival time

median disease progression time

effective rate (RR=1.02

95%CI=0.89 and 1.15)

and 1- and 2-year survival rates (RR=1.07

95%CI=0.93 and 1.24; RR=1.02

95%CI=0.66 and 1.58) of patients with NSCLC were similar for the DP or GP in combination with cisplatin. The incidence of severe (3 to 4 grade) thrombocytopenia (RR=5.22

95%CI=2.97 and 9.18)

anemia (RR=1.76

95%CI=1.30 and 2.38)

nausea and vomiting (RR=1.29

95%CI=1.04 and 1.60) was higher in combined GP and cisplatin regimen than in combined DP and cisplatin regimen

while the incidence of severe leukocytopenia (RR=0.71

95%CI=0.56 and 0.89) and diarrhea (RR=0.30，95%CI=0.15 and 0.60) was lower in combined GP and cisplatin regimen than in combined DP and cisplatin regimen. Conclusion The effect of the two regimens is similar for advanced NSCLC. The selection of them depends on the toxicity of drugs used and the tolerance of patients.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Oncolytic influenza virus enhances killing effect of gemcitabine against pancreatic cancer cells—MENG Zihe^1,2, XU Yongru², DENG Zhaoda², ZHANG Yuxin^1,2, YANG Penghui^1,2, HU Ruiping¹ ¹College of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot, Inner Mongolia;²Institute of Hepato-Pancreato-Biliary Surgery, First Medical Center, Chinese PLA General Hospital, Beijing, China

Gemcitabine induces autophagy in human bladder cancer T24 cells

Effectiveness and safety of paclitaxel liposome in combination with cisplatin as first-line chemotherapy for advanced squamous lung cancer

Efficiency and toxic reaction of nedaplatin combined with gemcitabine or paclitaxel in treatment of advanced non-small cell lung cancer: report of 133 cases

Drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in treatment of advanced non-small cell lung cancer—A new dawn in challenge

Related Author

徐永茹

邓肇达

张雨欣

杨鹏辉

扈瑞平

孟子鹤

何卫阳

杨潇宇

Related Institution

内蒙古医科大学基础医学院

中国人民解放军总医院第一医学中心肝胆胰外科医学部研究所

⁰